The history of angiogenesis inhibitors. (Q53184010)

12 May 2018

editorial

0 references

title

The history of angiogenesis inhibitors. (English)

1 reference

12 May 2018

main subject

angiogenesis inhibitor

1 reference

Ribatti D

1

1 reference

12 May 2018

publication date

1 August 2007

1 reference

12 May 2018

published in

Leukemia

1 reference

12 May 2018

volume

21

1 reference

12 May 2018

issue

8

1 reference

12 May 2018

page(s)

1606-1609

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404756

exact match

0 references

cites work

Inhibition of Cell Motility by Interferon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Control of tumor growth in animals by infusion of an angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Identification of an Inhibitor of Neovascularization from Cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Endothelial cell proliferation as a novel approach to targeting tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Disrupting tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Therapeutic renaissance of thalidomide in the treatment of haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Endostatin's antiangiogenic signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Metronomic therapy from a pharmacologist's view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Protamine is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

Transplacental carcinogenesis by stilbestrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

Growth Inhibition of Murine Melanoma and Human Colon Carcinoma by Recombinant Human Platelet Factor 4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

Angiogenesis inhibitors revised and revived at AACR

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404756

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404756

1 reference

12 May 2018

PubMed ID

17637715

1 reference

12 May 2018